Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | KDM4B | O94953 | 1/20 | 0.47 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 6/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.40 |
| ▸ | DPYD | Q12882 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 3/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.35 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245955 | 0.93 | KDM4C (0.47) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| Trifluoroacetic Acid SCHEMBL17727786 | 0.87 | PARP1 (0.39) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL16139620 | 0.78 | KDM5C (0.47) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL22305924 | 0.78 | KDM5C (0.47) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL17164016 | 0.78 | GSK3B (0.48) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL24556549 | 0.78 | KDM4C (0.47) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL17163962 | 0.78 | KDM4C (0.47) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| Bromide SCHEMBL14969315 | 0.76 | KDM5C (0.46) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL24941862 | 0.76 | PARP1 (0.69) | KDM4CKDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL245511 | 0.75 | DYRK1A (0.61) | PIM1HASPINGSK3BDYRK1ANFATC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| EP-2935253-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | Zenith Epigenetics Corp. (CA) | 2015-10-28 | — | — | EP | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791113-B2 | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| WO-2014096965-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2014-06-26 | — | — | WO | disclosed |
| EP-2585461-A1 | 2,4- DIARYL - SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | Merck Patent GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | KDM4C 1072/4885KDM4A 1532/4885KDM4B 1453/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | KDM4C 1137/4885KDM4A 1477/4885KDM4B 1346/4885 |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | KDM4C 2264/4885KDM4A 1804/4885KDM4B 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.